A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when immunised four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from birth
- Protection possible with 2-week gap before early delivery
- Vaccination during third trimester still provides significant protection for infants
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a comprehensive study undertaken in England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing robust and representative information of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The scope of this study gives healthcare professionals and expectant parents with trust in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s essential role in reducing the risk of serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured practical outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for infected babies to feed and breathe effectively. Parents commonly see their babies fighting for breath, their chests rising whilst they attempt to draw enough air into their damaged lungs. Whilst the majority of babies improve through supportive care, a small but significant number die from RSV-related complications annually, making vaccination as prevention a vital health service objective for safeguarding the most vulnerable and youngest members of society.
- RSV triggers lung inflammation, resulting in severe breathing difficulties in babies
- Approximately half of newborns contract the virus during their first few months alive
- Symptoms vary between mild colds to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants require serious hospital care for RSV annually
- Few babies succumb to RSV related complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have stressed the importance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.
The messaging from health authorities remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts rolling out diverse outreach initiatives to reach women during pregnancy
- Regional disparities in immunisation take-up throughout England require targeted improvement
- Local healthcare systems modifying schemes to align with specific population needs
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides tangible benefits for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the introduction of this safeguarding intervention, the 80% reduction in admissions equates to thousands of infants spared from serious illness. Parents no longer face the distressing scenario of watching their newborns labour to breathe or labour to feed, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, providing expectant mothers a active means to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection caused devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s advocacy for the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women during their third trimester, transforming what was once an inevitable seasonal threat into a manageable health risk.